LAB 241115 5.00P (LAB241115P5000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

LAB241115P5000

Watchlist

0.00
0.000.00%

15min DelayClose Oct 31 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

TD Cowen Maintains Standard BioTools(LAB.US) With Buy Rating, Maintains Target Price $2.5
Moomoo NewsOct 31 08:31 ET · Ratings
Standard BioTools to Participate in Upcoming Investor Conferences
GlobeNewswireOct 31 08:01 ET
TD Cowen Maintains Standard BioTools(LAB.US) With Buy Rating, Cuts Target Price to $2.5
Moomoo NewsOct 30 21:31 ET · Ratings
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript Summary
moomoo AIOct 30 19:23 ET · Conference Call
Standard BioTools GAAP EPS of -$0.07 Beats by $0.03, Revenue of $44.96M Beats by $3.96M
Seeking AlphaOct 30 16:59 ET
Earnings Flash (LAB) STANDARD BIOTOOLS Reports Q3 Revenue $45M
MT NewswiresOct 30 16:45 ET

Comments

Jaguar8

Sep 24 07:04

NEWS

$Standard BioTools (LAB.US)$
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), today announced that the SomaScan® 11K Platform now includes protein measurements on a broader range of sample types, including cerebrospinal fluid (CSF), aqueous humor, tissue homogenates and cell lysates. The SomaScan® Platf...

MARKET-TEST-DUMMY

Jul 25 09:18

Insider buying

$Standard BioTools (LAB.US)$

MARKET-TEST-DUMMY

Jun 5 15:13

Keep trying

$Standard BioTools (LAB.US)$

Trytosaveabit

May 28 15:05

Hmm

$Standard BioTools (LAB.US)$ Standard BioTools Purchases the Carterra® Lsa-Xt System to Accelerate Data Delivery and Provide Greater Validation to Somascan Customers

Trytosaveabit

May 8 15:23

Decent

$Standard BioTools (LAB.US)$ Revenue was $46 million, up 81% year-over-year, with impact of SomaScan
assay services, kits and related revenue in 2024; and
-- Ended the quarter with cash, cash equivalents, restricted cash and
short-term investments of $464 million, after accounting for $71 million
cash payments for merger-related expenses, settlement of year-end
operating accruals, debt retirement and completed stock buybacks.